Earnings call transcript: Perimeter Medical’s Q2 2025 sees revenue surge but net loss widens

Perimeter Medical Imaging AI Inc., with a market capitalization of $128.42 million, reported a significant increase in revenue for Q2 2025, with a 105% jump from the previous year. Despite this growth, the company faced a widening net loss. The stock price responded with a 6.38% decline, closing at $0.235, amidst broader market pressures. According to InvestingPro data, the company’s stock has shown notable volatility, trading between $26.10 and $33.34 over the past 52 weeks.

Key Takeaways

• Revenue increased by 105% year-over-year, reaching $506,000.
• Operating expenses improved by 22%, yet net loss widened to $3.9 million.
• Stock price dropped by 6.38% following the earnings report.
• FDA approval for B Series OCT expected by late Q4 2025 or Q1 2026.
• Expansion plans include international markets and a larger commercial team.

Company Performance

Perimeter Medical’s Q2 2025 performance was marked by a notable revenue increase, driven by heightened demand for its imaging technology. Despite the revenue boost, the company’s net loss widened to $3.9 million from $3.2 million in the previous year. This reflects ongoing investment in product development and market expansion.

Financial Highlights

• Revenue: $506,000, a 105% increase from Q2 2024.
• Gross Margin: 70%, unchanged from the previous year.
• Operating Expenses: $4.3 million, a 22% improvement from $5.5 million in 2024.
• Net Loss: $3.9 million, compared to $3.2 million in the prior period.
• Cash and Cash Equivalents: $1.4 million, with additional funds expected from offerings and grants.

Outlook & Guidance

Perimeter Medical anticipates FDA approval for its B Series OCT with ImageAssist AI 2.0 by late Q4 2025 or Q1 2026. The company is preparing for an aggressive commercial launch and expanding its commercial team to meet growing demand. International market expansion is also on the horizon.

Executive Commentary

Dr. Alastair Thompson, Principal Investigator, emphasized the importance of intraoperative margin assessment, stating, "Today, intraoperative margin assessment remains one of the most pressing problems for both surgeons and their patients." CEO Adrian Mendez highlighted the growing demand, noting, "We’re seeing very strong demand. And so the thing that’s limiting us right now, quite frankly, is the size of our commercial team."

Risks and Challenges

• Regulatory Approval: Delays in FDA approval could impact launch timelines.
• Financial Health: The widening net loss and limited cash reserves pose financial sustainability risks.
• Market Competition: Competing technologies could challenge market share.
• Operational Scale: The need for a larger commercial team may strain resources.

Perimeter Medical’s Q2 2025 results reflect both opportunities and challenges as the company navigates growth in a competitive market. The upcoming FDA decision and strategic expansion efforts will be critical for future performance.

Full transcript - Perimeter Medical Imaging AI Inc (PINK) Q2 2025:

Conference Operator: Afternoon, ladies and gentlemen, and welcome to the Perimeter Medical Second Quarter twenty twenty five Conference Call. At this time, all lines are in listen only mode. Following the presentation, we will conduct a question and answer session. This call is being recorded on Tuesday, 08/26/2025. I would now like to turn the conference over to Stephen Kilmer, Investor Relations.

Please go ahead.

Stephen Kilmer, Investor Relations, Perimeter Medical: Thank you. Good afternoon, everyone. Let me start by pointing out that this conference call will include forward looking statements within the meaning of applicable securities laws. These may include statements regarding the future financial position, business strategy and strategic goals, commercial activities and timing, competitive conditions, research and development activities, projected costs and capital expenditures, research and clinical testing outcomes, the potential benefits of our products, including Perimeter S Series OCT, Perimeter B Series OCT and Perimeter ImageAssist, Perimeter’s ability to broaden its user base and the expected approval of its proprietary AI, expectations regarding new products and the timing thereof and expectations regarding opportunities for market expansion. Forward looking statements are subject to numerous risks and uncertainties, many of which are beyond our control, including the risks and uncertainties described from time to time in our public filings and press releases, which are posted on cedarplus.ca.

Our results may differ materially from those projected on today’s call. No forward looking statement can be guaranteed. Perimeter undertakes no obligation to publicly update or revise any forward looking statement, whether as a result of new information, future events or otherwise, other than as required by law. For the benefit of those who are new to the Perimeter story, I would also like to take a moment to summarize our business. We are a medical technology company working to transform cancer surgery with ultra high resolution real time advanced imaging tools to address areas of high unmet medical need.

We are currently commercializing our FDA cleared Perimeter S Series OCT system, which provides real time cross sectional visualization of excise tissues at the cellular level. Our breakthrough device designated investigational perimeter B Series OCT system, which combines our proprietary image assist artificial intelligence technology with wide field optical coherence tomography represents our next generation device. As we will discuss in more detail today, B Series OCT with ImageAssist AI two point zero has recently been evaluated in the pivotal clinical trial in breast conserving cancer surgeries or BCS. And our premarket approval application for the device is currently under review by the U. S.

Food and Drug Administration. On the call representing the company are Adrian Mendez, Chief Executive Officer Andrew Berkley, Perimeter’s Chief Innovation Officer and Co Founder Paulo Dipascalis, our Vice President of Corporate Development and Sarah Brahed, the company’s Chief Financial Officer. With that said, I’ll now turn the call over to Sarah.

Sarah Brahed, Chief Financial Officer, Perimeter Medical: Thanks, Steve. Good afternoon, everyone, and welcome to our second quarter twenty twenty five conference call. On behalf of the management team and everyone at Perimeter, I would like to thank you for your ongoing interest in our company. For those of you who are our shareholders, we appreciate your continued interest and support. I’ll turn the call over to Adrienne in a moment.

However, before I do, I’d like to provide a brief update on our financial results. To streamline things, all the numbers we will refer to have been rounded, so they are approximate. As a reminder, we also report in U. S. Dollars.

For the three month period ended 06/30/2025, the company recorded revenue of $506,000 consisted of the sale of consumables and the sale of ESP warranty programs. This represents a 105% increase over Q2 twenty twenty four. Gross margin for the 2025 was 70%, essentially unchanged from the same period in 2024. Operating expenses for the second quarter were $4,300,000 a 22% improvement from $5,500,000 in the same period in 2024. Additional cash conservation efforts were implemented at the end of Q2 with the associated cost savings expected to be realized in Q3 and onwards.

Second quarter twenty twenty five net loss was $3,900,000 compared to $3,200,000 in the three months ended 06/30/2025. As of 06/30/2025, cash and cash equivalents were approximately $1,400,000 This amount does not include the $1,600,000 gross proceeds from the second and final closing of the company’s recent prospective offering nor a Cancer Prevention and Research Institute of Texas secret grant receivable of $745,000 which is related to the reimbursement of the pivotal clinical trial project costs. With that, I’ll now turn over the call to Adrian.

Adrian Mendez, Chief Executive Officer, Perimeter Medical: Thanks, Sarah, and thanks again, everyone, for your time and attention today. As you can see from what Sarah just reviewed, we had an exciting and productive second quarter. And while that progress continues in every front within the company, we’re carefully managing our resources as we continue to commercialize our current S Series device and at the same time, lay the groundwork for what we expect will be an aggressive and successful rollout of our next generation B series device starting in the next few months pending FDA approval. The F Series OCT, which is our first FDA cleared intraoperative imaging technology, provides surgeons with image resolution capable of visualizing tissue structures at the cellular level down to the critical two millimeter depth while assessing margins real time in the Operating Room. It is cleared under a general indication, which has not been evaluated by the FDA specifically for use in breast tissue, breast cancer and other types of cancer margin evaluation and reducing re excision rates.

Our goal has been to seed the market with S Series OCT in order to create a strong network of early adopters and technology champions in preparation for a potential FDA clearance of our B Series OCT with ImageAssist AI two point zero. We’ve done better than that. In fact, while it may seem counterintuitive, adoption of the S Series in terms of both new system placements and increased current device utilization has been accelerating while we wait for the requisite go ahead from the FDA to introduce the AI driven B Series to the market. To put that into perspective, revenue in the first six months of twenty twenty five alone was 25% higher than the total for all of 2024. And we’re excited to see utilization rates increasing 93% year over year and 35% sequentially quarter over quarter as this further validates the specific need for our margin assessment technology at the surgical level.

In fact, we recently surpassed a significant case volume milestone with surgeons now having imaged over 3,000 patients in the Operating Room. With respect to our upcoming B Series, as you know, we filed our premarket approval application for the device with the FDA in mid March. On the heels of that, in May, Doctor. Alastair Thompson, the principal investigator for the pivotal trial of the Perimeter B series, which supported the FDA PMA application presented previously embargoed detailed study results to an overly packed audience of researchers and clinicians at ASBRF, the world’s premier breast cancer surgery conference. While I won’t take time to go over the trial specific findings here again, I would like to reiterate what Doctor.

Thompson said about the results. To quote, Today, intraoperative margin assessment remains one of the most pressing problems for both surgeons and their patients. The final results of this pivotal trial clearly demonstrate that the use of Perimeter B Series has the potential to change the current paradigm by empowering surgeons to identify regions of interest, enhance real time intraoperative decision making and reduce the incidence of re excision due to unaddressed residual disease following lumpectomy. That statement from an important opinion leader clearly validates what we have said before. The ultimate product promise of Perimeter B Series is greater peace of mind, both for the breast cancer surgeon who, no matter how skilled, currently faces a nearly one in five reoperation rate due to positive margins, and for their breast cancer patient and family who, under the current paradigm, typically have to wait and worry for up to ten days for their surgeon to receive a postoperative pathology report, which will determine whether they will have to go through the emotional and physical trauma of a second surgery due to cancer left behind.

There is no question that the PMA submission for Perimeter B series, which has FDA breakthrough device designation, was a major milestone achievement. Our first regulatory approval application for our AI enabled wide field OCT technology as well as for a specific indication label. But we’re not sitting back to watch and wait. Instead, we are aggressively commercializing our current S series device, while at the same time, we continue to have good dialogue with the agency as it reviews the PMA application for our next generation B Series. And to further position us for continued sales success and growth, we’ve added two key people with deep expertise to our leadership team.

Abby Goodman has been appointed Vice President of Sales and Paolo DiPasquale, who’s on this call, has joined us as our VP of Corporate Development. Abby brings over twenty years of medical device sales experience, most recently serving as ProFound Medical’s Global Chief Commercial Officer. Prior to joining ProFound, she progressed through a variety of senior leadership sales roles within Hologic, Novodak Technologies, Covidian and Dupuy Mitek. Paolo brings a unique perspective as someone who has over 17 of experience in The U. S.

And Canadian capital markets across equity research, institutional equity and investment banking at Canaccord Genuity and Stephens. And so to summarize, we are seeing continuing positive commercial traction with our current S Series product as demonstrated by our 105% revenue growth, record patient cases and growing installed base in the second quarter. At the same time, we are carefully managing our resources as we grow. And as a result of our cost control efforts, we expect additional cost savings to result in an approximate 30% reduction in total operating costs starting in the current third quarter. In November 2024, we announced that the pivotal trial of our next generation AI enabled Perimeter B Series system met its primary endpoint, achieving a statistically significant reduction in patients with residual cancer during surgery.

These results demonstrate super superiority of the B Series ability to aid surgeons in achieving clear surgical margins during surgery, potentially lowering the need for reoperations. Based upon the positive trial results, we filed the FDA PMA application for the B Series OCT with Imagesys two point zero in mid March twenty twenty five. And we’ve been working closely with the agency since that time as it conducts a substantive review of the PMA application. While the timing is obviously outside of our control, right now we are hopeful that the FDA approval will come sometime in late Q4 twenty twenty five or Q1 twenty twenty six. Finally, if and when FDA clearance for PERIMITER B series is obtained, it will allow for a full and aggressive commercial launch of our next generation device, representing a major step in validating our AI’s application to intraoperative margin assessment.

And company specifically, our go to market strategy and opportunity to significantly broaden our OCT user base across The United States. As you can hopefully see from today’s press release and calls, we are quickly and confidently approaching the first of what I expect to be many potential major value inflection points for Perimeter. This is an exciting time for us, and we look forward to keeping you updated on our progress. And with that, I will now open up the call for your questions. Operator?

Conference Operator: Ladies and gentlemen, we will now begin the question and answer session. The The first question comes from the line of Scott McAuley from Paradigm Capital. Please go ahead.

Scott McAuley, Analyst, Paradigm Capital: Afternoon, everyone. Thanks for taking the questions. I guess just an update on, I guess, the current total number of S series placements that are out there. And I saw in the press release and over the past few months, you know, there’s been two new announcements of new systems, so maybe kind of the total and then how many you’ve added in the past quarter or so.

Adrian Mendez, Chief Executive Officer, Perimeter Medical: Yeah. Sure. Sarah, do you want to take that question?

Sarah Brahed, Chief Financial Officer, Perimeter Medical: Sure. Thanks, Scott. Yeah. We have 20 total and one new added in q two.

Scott McAuley, Analyst, Paradigm Capital: That’s great. And I guess both for those systems as well as kind of the interest you’re seeing in the pipeline in terms of capital placements versus pay per use? Is there any kind of evolution of that? Is it relatively constant? And yes, what are people saying in terms of which model they prefer?

Adrian Mendez, Chief Executive Officer, Perimeter Medical: Yeah. It’s a great question, Scott. So as you know, over the past few months, we’ve, actually sold capital to some of our customers, which is a change in the business model. I guess I’d say more of an evolution of the business model from the placements at no charge that we’ve historically had. Our philosophy, our approach really is to meet the customer where they’re at.

There are some that, won’t do placements at no charge, and they’ll only do capital purchases. There are some that where it’s easier to get through the, approval processes, by doing a pay as you go type of model. There’s some hospitals that have foundations that are willing to put some money up for the machine itself. And we’re open to all those possibilities. So I think what’s happening generally, though, is as we’re getting more and more usage out there, more surgeons have been on the device, some sort of more, the benefits of the product getting out into the marketplace, we’re starting to see more interest and more willingness to have a capital purchase approach versus a pay as you go.

So from our standpoint, we look at every deal individually, and we’ll do what we need to do to get the customer on board and get that utilization up. But of course, we’re looking to see what has the biggest impact us from a financial perspective at the same time.

Scott McAuley, Analyst, Paradigm Capital: That’s great. And I guess is there any way you can kind of characterize the current pipeline for that series? And especially if that’s accelerated post the American Society of Breast Surgeons conference and the presentation of the positive trial data?

Adrian Mendez, Chief Executive Officer, Perimeter Medical: Yeah. Actually, it’s been so that conference, that was a few months ago, as mentioned, is where the results from our clinical trials were sent up by Doctor. Alastair Thompson. The quote I quoted was from him, at that time. A lot of interest after that.

Getting that data out into the open, from the trial, has been very well received. The pipeline continues to grow very, very strongly. And the nice thing about it is you know, with the b series, the AI enabled device coming on to market, hopefully, end of this year, early next year, we’re actually seeing demand for current product right now, the s series. We’ve got customers, potential customers who are looking and saying, hey. Look.

I can see what has been able to be done with the product already, the s series. I understand that the b series has all kinds of additional benefits, but I really want to bring something into my hospital today to help my patients today, to help my practice today. So the acceleration of the pipeline, build of the pipeline is you know, I’m I’m I’m I like it because it’s not just futures where people are saying, okay. Great. Now I’ll buy from you a year from now.

It’s actually customers who are expressing interest today, and that we’re able to engage with today. So I I think that’s, you know, that that that’s strong, really strong for what we’re talking about in terms of not only seeding the market, but also being aggressive as aggressive as we can to bring customers and revenue onboard immediately.

Scott McAuley, Analyst, Paradigm Capital: Makes sense. That’s great to hear. Things are things are picking up. I guess just on the balance sheet quickly, good to hear that 30% operating cost reduction target. Just to clarify, is that quarter over quarter, so kind of q three expected versus q two, or is that year over year?

And maybe a little bit about kinda how that’s being achieved.

Adrian Mendez, Chief Executive Officer, Perimeter Medical: Yes. Sarah, why don’t you take that?

Sarah Brahed, Chief Financial Officer, Perimeter Medical: Yeah. Thanks, Scott. I mean, ideally, on quarter, some of it’s gonna be timing related. So we’re expecting at least a 30% reduction versus prior quarter, so over q two. Timing, we’ll see how that works out, but that’s the plan.

And really, you know, what we’re doing is we we focus the cost reduction efforts on cash conservation to focus on the b series FDA submission activities and prelaunch activities. So really focusing the organization inside of the commercial team on those activities.

Scott McAuley, Analyst, Paradigm Capital: That’s great. And I guess lastly, for me, I’ll hop back in the queue, is is the, current cash runway. Do you expect, with the added cash from the financing and the grant reimbursement and the operating cost reductions to see you through to the FDA approval?

Sarah Brahed, Chief Financial Officer, Perimeter Medical: All right, if I’ll take that one. I mean, I think we’re always going be in a position where we need to be looking to strengthen the balance sheet. We’re making best efforts to reduce spend and increase runway. So, you know, I think it’s all about timing and being opportunistic at when we can execute on, you know, shoring up balance sheet while also managing milestones.

Scott McAuley, Analyst, Paradigm Capital: Makes sense. Thanks all for taking the questions, and have a good afternoon.

Adrian Mendez, Chief Executive Officer, Perimeter Medical: Scott, I’ll just add some which is that to your question about the pipeline on the heels of ASBRS, we’re seeing very strong demand. And so the thing that’s limiting us right now, quite frankly, is is the size of our commercial team. So bringing cash onto the balance sheet to accelerate that is a high ROI activity. Right? So so then the balance that we have to make is between, between a runway and being able to bring those customers on board more quickly.

So this this is sort of like from a management standpoint. This is what we’re working through internally But the nice thing is we have the demand out there. We can take it down, and we’re only limited by the size of our commercial team at this

Conference Operator: Your next question is from the line of Doug Loe from Lida Financial. Please go ahead.

Doug Loe, Analyst, Lida Financial: Yes. Thanks, operator, and good afternoon all. Adrian, I have a different question that I’ll jump in on in a second. But just in response to your commentary there about marketing infrastructure being limiting for S Series adoption. Is do you think you could cost effectively add to your team before B Series is approved?

Fingers crossed, as you say, later this year, probably early in Q1 twenty twenty six? Or is augmenting sales and marketing expense something you might more prudently add to once B Series is approved and there’s some awareness of its availability in The U. S. Market?

Adrian Mendez, Chief Executive Officer, Perimeter Medical: I think it’s so it first of hi, Doug. It’s Tasiu again. It’s so so it it it has two phases. Right? One is adding players to the team, adding adding the folks to the organization.

And then the second is when do the results of that appear in the finances and sales? They you know, these have a relatively long sales cycle, you know, up to six months or so, from the time you start start to engage with customers till when it comes through. So this is the balancing act that we need to have, which is the combination of how when do we hire the salespeople, and then when do they expect to deliver, and then how do we map this into both our cash, you know, our resources that we have right now and then the speed at which we’d accelerate? All of that, living in the ambiguity of when FDA approval will come in, which is likely the end of this year or early next year. So this is this is kind of how we’re looking through that.

My that’s the lens we will look to that. Right? So that’s a high level overlay. And then to your specific question is there will be some amounts of t of commercial that we hire before we get FDA approval, and there’ll be some that we hire after. So it’ll be a mix of both.

And the balance between the two is dependent sort of on as we progress when we expect that FDA approval really to come in as we are closer to the date.

Doug Loe, Analyst, Lida Financial: Yes. Appreciate the color. No, it’s a tough call as to what when you add marketing infrastructure in comparison to the sales believe product. So thanks for that. My question is going to be, I was just wondering how your focus needs to be on U.

S. B Series sales once the device becomes approved and available, which we all expect. But how should we be thinking about international market opportunities? Is Europe a market where radical or partial lumpectomies are routinely conducted to a pace that we see in North America, which makes B Series and S Series adoption relevant here. And other international markets, I mean, does it make sense to pursue regulatory approval in specifically in Western Europe, but in other markets?

And do you think you could cost effectively exploit those markets with a marketing team that would be comparable to what you’re putting in place here? And I’ll leave it there. Thanks.

Adrian Mendez, Chief Executive Officer, Perimeter Medical: Yeah. I think, I mean, step one is we have to get through the FDA approval, and then build out and start to get the traction in our own backyards. Margin assessment is a problem that affects everyone all over the world. It doesn’t stop at the borders. Cancer, generally, The U.

S. Is about fifteen percent of all the diagnosed cancer cases in the world. So there’s a big market outside The U. S. And one that we can’t have a blind eye to.

So the full expectation we do expand outside of The U. S. But having that FDA approval in hand makes it a lot easier to move to the next steps. So definitely parts of the plan, but at the right time.

Doug Loe, Analyst, Lida Financial: Yep. Good answer. Thanks very much. That’s it for me.

Conference Operator: Thank you very much. There are no further questions at this time. I’d like to turn the call back to Adrian Mendez for closing comments. Sir, please go ahead.

Adrian Mendez, Chief Executive Officer, Perimeter Medical: Okay. Great. Thank you. And thanks, everyone, again for joining us today. It’s a really exciting time for the company.

And so as always, we appreciate your ongoing support, and look forward to reporting continued progress as we commercialize our OCT technology. Thank you.

Conference Operator: Ladies and gentlemen, this concludes today’s conference call. Thank you very much for your participation. You may now disconnect.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.